Trevi Therapeutics, Inc. (NASDAQ: TRVI) completed a $173 million underwritten public offering of 13,340,000 shares of common stock at $13.00 per share. The offering included an additional 1,740,000 shares that were issued when the underwriters exercised their option, bringing total proceeds to approximately $173 million before underwriting discounts and commissions.
The capital infusion expands Trevi’s cash reserves, which stood at $171.8 million as of March 31, 2026, and adds to the $188.3 million in cash, equivalents, and marketable securities reported at the end of FY25. Management estimates that the new cash will extend the company’s runway through 2029, reducing the need for additional financing and limiting dilution for existing shareholders.
The proceeds will fund the company’s planned Phase 2b trials in non‑idiopathic pulmonary fibrosis interstitial lung disease and refractory chronic cough, as well as two Phase 3 trials for idiopathic pulmonary fibrosis–related chronic cough. Phase 3 enrollment is slated to begin in the second quarter of 2026, with the first trial’s topline expected in the first half of 2028 and the second in the second half of 2027. An adaptive Phase 2b trial for non‑IPF ILD–related chronic cough is scheduled for the second half of 2026.
CEO Jennifer Good emphasized that the financing “extends our cash runway through 2029, which will fund the potential approval of Haduvio in idiopathic pulmonary fibrosis–related cough and fund the development work in chronic cough in other interstitial lung disease and refractory chronic cough.” The company’s Haduvio program has shown statistically significant reductions in cough frequency in Phase II studies and is the focus of the current clinical development strategy.
The market has historically reacted to equity issuances with a short‑term dilution concern, a typical response to new share issuance. Despite this, the full exercise of the underwriters’ option indicates strong demand for the offering and reaffirms investor confidence in Trevi’s pipeline and strategy.
Overall, the successful completion of the offering provides Trevi with the financial resources to advance its lead candidate through critical late‑stage trials, strengthens its balance sheet, and positions the company for potential regulatory approvals in the coming years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.